FDA approves third new targeted therapy for advanced RCC – UrologyTimes
The FDA has approved the enzyme inhibitor temsirolimus (Torisel) for the treatment of advanced renal cell carcinoma.
The approval of temsirolimus follows the December 2005 approval of sorafenib (Nexavar) and the January 2006 approval of sunitinib (Sutent), which represent a new class of targeted therapies for advanced RCC.
The article in the New England Journal of Medicine showed an improvement in survival of 3 months with temsirolimus. This will be an important addition in helping patients with advanced kidney cancer.